all the us That's you of great. Thanks, call morning. for on Shannon, to thanks this joining and
Beyond commercialization losmapimod. with progress quarter and and we our are stage our clinical for excited Sanofi of the license pociredir, X of collaboration assets, to and announce losmapimod super agreement another solid across development
start collaboration So this just structure of what importance I'd like and strategic of off by an overview provide this Sanofi. the is with morning doing to
for launch U.S. what In This commercial and capabilities combines focus and the efforts do strong allows Fulcrum that allow rights FSHD collaboration will to exclusive in both commercial best. a XXXX. planning losmapimod U.S., exceptional parties countries regulatory, outside development will across the we on It U.S. obtain with brief, for Sanofi outside of do our each to Fulcrum's XXX Sanofi's expertise in approximately commercialization
is and execution we the with on inherent we commitment look its addressing its we could to company shared partner and our patients of forward unmet losmapimod, have will for for first believe patients FSHD. need launch commercial delivering us to our undertaking reach best than any ex-U.S. partner typically the possible mitigates on selected risk We in own. product biotech markets own Sanofi a quicker on like that allow having the commercial the Importantly, do to of
We're going in of to pleased low $XX also with in development equally with The deal regulatory companies terms, cycle. teens U.S. share fund over global of additional the in eligible ex-U.S. $XXX us enables million value in to in along losmapimod the losmapimod which nondilutive receive both We're term we with the starting up the life which capital. of also launch upfront, and allows and to substantial the losmapimod net us will short, product's specific the annual very receive the tiered also near an In million to retain of forward. milestones, royalties the outside sales sales for will cost U.S. the
near-term Patrick two Dr. take on in clinical to the providing rare before Officer, late our the newly would losmapimod, regulatory appointed accomplished Horn, I successfully our space multiple veteran complementary emergency. inflection of Iain that ideal and to is launch. are account well a of does toward we apologies as Fraser, his today's an approval This positioned we time points. on meeting industry clinical disease Chief development, an an he expertise appointment, is Now who has Pat's and Medical also the family opportunity with pociredir and through Dr. advance attend for update welcome Pat to send commercial guided like unable assets, therapies
selective inhibitor with kinase death know, program, small and FSHD. which, molecule losmapimod, pXX let's advanced MAP alpha/beta that is So inhibits expression DUXX patients thus prevent with most oral bit most in go deeper an a our downstream you as and start muscle of
is disease a muscle for mobility. but characterized of significant become the these daily after loss muscle extremity impairment perform FSHD there the are by rare and I a relentless disease. FSHD approved muscular treatment of reminder, in quick FSHD of a and for function life and estimated an with patients, is options that form activities degree population are There unable dystrophy heterogeneity of XX,XXX. function of significant which thus many As of U.S. year, patient upper slow for you wheelchair take year onset a prevalent this bound. no resulting and of to in And while Ultimately, unmet debilitating FSHD, granted patients XX% currently unable are to patients progression need live independently. underscores is
functional to Phase outcomes was workspace, patients treated outcomes by in recently benefit trial, fat muscle II by published in placebo. month reachable with improvement in demonstrated study, and tolerability ReDUXX last the Neurology patients. observed losmapimod structural III compared for our as as September of total trial outcomes and Our enrollment clinical in losmapimod, as with trial year the Building Phase and measured II XXX we Lancet of completed for measured infiltration Phase favorable a last patient-reported in encouraging on all our global
patients the these And in of as to move patients II period, the phase this blinded and indicative patients XX-week for trial extension the of completed of need percentage the our high opting fashion. into clinical XXX XXX end patients high very is April into observed similar unmet Phase XXX study open-label This and clinical of in fully open-label had to of year, the with FSHD. to of what continue of elected was the treatment a the of
with bring fourth line We are patients year, report on the first-ever closer for the in therapy which will quarter to one step this FSHD. delivering us of FDA-approved top track to
motion geographies. range area or endpoint well-powered for been abilities workspace. of is the of of activities evaluate which baseline a RSA of quantitative XD motion technology is mobility trial, using and REACH sensor correlate measure to and relative a registration a to extremity The U.S. to intended in specifically living. RSA, surface perform upper assessment muscle has Now Phase the as our is and shown reminder, REACH quick that function with arm the it enabling reachable daily certain shoulder primary change in both for the in III trial, be XX-week is trial a and ex-U.S.
particular, demonstrated patients. Assessment change RSA which relative at a net Clinical II and with interactions the placebo or Based meaningful Phase FDA, to score score RSA COA the Group in the on currently in XX% XX the change specific to collaborative with our to assessing are extent Outcomes in is our at we a weeks. study, FDA In losmapimod
Additionally, a launch that dynamometry; strategy key of our and secondary utilization the here infiltration measures which self-reported include muscle measured thinking fat quality marker endpoints well or U.S. important on help in whole-body pathology MFI, shoulder our disease as care commercial as begin for inform life of health questionnaires will we an MRI; payer is by as
important Fulcrum take position commercial for Taken together, we to forward continue readiness. to steps
makes pociredir, is lifelong million inherited potential HbF and This disorder people or patients U.S. a fetal worldwide. the of one SCD, most sickle validated approximately that the cell blood rationale diseases. oral of for for impairs to people The XXX,XXX or our HbF SCD quality severely with X.X hematologic sure. inducer prevalent turning the in disease of therapeutic hemoglobin life of a for sickle Now for approximately elevation treatment disease cell nonmalignant
these of the a and unmet believe approval option recently, symptomatology. focus scientific relief. there gene Now SCD But historically, for a safe for all progress the high approaches, of need SCD broadly symptom of remains while therapeutic only pain and advancement standard has the transfusions, of exciting has that and on editing medications blood accessible enabled treatment hydroxyurea. protective treatments And more therapeutic we involved are
small first-in-class we unmet molecule a the need. As believe inducer, to potential oral address has HbF pociredir this
the there to FDA So PIONEER note treatment August X-month lifted on study. in hold dose XXXX, important or the the we call Phase It's in clinical protocol-defined changes the were of the the Ib scheme duration. study escalation no
work dose in Cohort study dose for have the Ib at XX at dosing of a We the followed XX-milligram the are once months, SCD expected with community. by to X pociredir X Both and X X to once to XX-milligram the enroll continue new the daily Phase are daily duration physicians reinitiate and expeditiously of months. approximately with will PIONEER sites activated also patients. leading relationships cohorts key Cohort trial building evaluate we several
-- pociredir believe an in patients in and living need sickle HbF cell We unmet the this priority hold, provide a XX%. severity. prior specifically, a only disease. as to in to observed on XX build us pociredir ahead. to that significant in percentage demonstrated has to of magnitude treatment, improvement a increase from to point We the translate disease building HbF clinical we option XX cell oral meaningful HbF look for therapeutic clinical sickle encouraging community the of a More key we the total HbF data a years on approximately after Addressing cell the could momentum potential up that that of the baseline days total with excited into are inducer for differentiated obtained in remains which sickle forward increased or
Musso, me update financials. on And turn run to Chief now it Officer, you. let with over so Alan to through our Alan, to over that our business, the Financial
